-+ 0.00%
-+ 0.00%
-+ 0.00%

BioMimetix Announces Publication of Phase I/II Clinical Trial Evaluating BMX-001 in Patients With Locally Advanced Head and Neck Cancer

Barchart·11/19/2026 08:08:00
Listen to the news

Results demonstrate a favorable safety profile and reduction of treatment-related toxicities during chemoradiation therapy

ENGLEWOOD, Colo., Nov. 19, 2026 /PRNewswire/ -- BioMimetix JV, LLC today announced the publication of results from a NCI funded multicenter Phase I/II clinical trial evaluating BMX-001, a redox-active metalloporphyrin compound, in patients undergoing chemoradiation for locally advanced head and neck squamous cell carcinoma (HNSCC).

Read more at prnewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.